Literature DB >> 20628413

The PSEN1 I143T mutation in a Swedish family with Alzheimer's disease: clinical report and quantification of Aβ in different brain regions.

Lina Keller1, Hedvig Welander, Huei-Hsin Chiang, Lars O Tjernberg, Inger Nennesmo, Asa K Wallin, Caroline Graff.   

Abstract

Early-onset dominantly inherited forms of Alzheimer's disease (AD) are rare, but studies of such cases have revealed important information about the disease mechanisms. Importantly, mutations in amyloid precursor protein (APP), presenilin 1 (PSEN1) and PSEN2, alter the APP processing and lead to an increased amyloid β-peptide (Aβ) 42/40 ratio. This, together with other studies on pathogenic mechanisms, show that Aβ42 is a major player in the etiology of AD. Here, we present a clinical and neuropathological description of a Swedish family with an I143T mutation in the PSEN1 gene, which gives rise to a severe form of AD. We also performed an extensive investigation on the concentration and distribution of Aβ species of different lengths in six brain regions from two mutation carriers. Our study showed that Aβ42 and a longer peptide, Aβ43, were present both in plaque cores and in total amyloid preparations, and were each clearly more frequent than Aβ40 in all examined regions, as shown by both mass spectrometry and immunohistochemistry.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20628413      PMCID: PMC2987466          DOI: 10.1038/ejhg.2010.107

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  25 in total

Review 1.  Alzheimer's disease: genes, proteins, and therapy.

Authors:  D J Selkoe
Journal:  Physiol Rev       Date:  2001-04       Impact factor: 37.312

2.  Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40.

Authors:  Samir Kumar-Singh; Jessie Theuns; Bianca Van Broeck; Daniel Pirici; Krist'l Vennekens; Ellen Corsmit; Marc Cruts; Bart Dermaut; Rong Wang; Christine Van Broeckhoven
Journal:  Hum Mutat       Date:  2006-07       Impact factor: 4.878

3.  Familial cases presenting very early onset autosomal dominant Alzheimer's disease with I143T in presenilin-1 gene: implication for genotype-phenotype correlation.

Authors:  Noritoshi Arai; Atsushi Kishino; Yuji Takahashi; Daiji Morita; Koichiro Nakamura; Takahiro Yokoyama; Tomoji Watanabe; Masayoshi Ida; Jun Goto; Shoji Tsuji
Journal:  Neurogenetics       Date:  2007-10-30       Impact factor: 2.660

4.  Screening for PS1 mutations in a referral-based series of AD cases: 21 novel mutations.

Authors:  E A Rogaeva; K C Fafel; Y Q Song; H Medeiros; C Sato; Y Liang; E Richard; E I Rogaev; P Frommelt; A D Sadovnick; W Meschino; K Rockwood; M A Boss; R Mayeux; P St George-Hyslop
Journal:  Neurology       Date:  2001-08-28       Impact factor: 9.910

5.  A unique gene expression signature discriminates familial Alzheimer's disease mutation carriers from their wild-type siblings.

Authors:  Yosuke Nagasaka; Karin Dillner; Hayao Ebise; Reiji Teramoto; Hiroyuki Nakagawa; Lena Lilius; Karin Axelman; Charlotte Forsell; Akira Ito; Bengt Winblad; Toru Kimura; Caroline Graff
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

6.  Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice.

Authors:  M Citron; D Westaway; W Xia; G Carlson; T Diehl; G Levesque; K Johnson-Wood; M Lee; P Seubert; A Davis; D Kholodenko; R Motter; R Sherrington; B Perry; H Yao; R Strome; I Lieberburg; J Rommens; S Kim; D Schenk; P Fraser; P St George Hyslop; D J Selkoe
Journal:  Nat Med       Date:  1997-01       Impact factor: 53.440

7.  Abeta43 is more frequent than Abeta40 in amyloid plaque cores from Alzheimer disease brains.

Authors:  Hedvig Welander; Jenny Frånberg; Caroline Graff; Erik Sundström; Bengt Winblad; Lars O Tjernberg
Journal:  J Neurochem       Date:  2009-05-15       Impact factor: 5.372

8.  Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.

Authors:  Jorge J Palop; Jeannie Chin; Erik D Roberson; Jun Wang; Myo T Thwin; Nga Bien-Ly; Jong Yoo; Kaitlyn O Ho; Gui-Qiu Yu; Anatol Kreitzer; Steven Finkbeiner; Jeffrey L Noebels; Lennart Mucke
Journal:  Neuron       Date:  2007-09-06       Impact factor: 17.173

Review 9.  Epilepsy and cognitive impairments in Alzheimer disease.

Authors:  Jorge J Palop; Lennart Mucke
Journal:  Arch Neurol       Date:  2009-02-09

Review 10.  Molecular genetics of Alzheimer's disease.

Authors:  M Cruts; C Van Broeckhoven
Journal:  Ann Med       Date:  1998-12       Impact factor: 4.709

View more
  13 in total

1.  Potent amyloidogenicity and pathogenicity of Aβ43.

Authors:  Takashi Saito; Takahiro Suemoto; Nathalie Brouwers; Kristel Sleegers; Satoru Funamoto; Naomi Mihira; Yukio Matsuba; Kazuyuki Yamada; Per Nilsson; Jiro Takano; Masaki Nishimura; Nobuhisa Iwata; Christine Van Broeckhoven; Yasuo Ihara; Takaomi C Saido
Journal:  Nat Neurosci       Date:  2011-07-03       Impact factor: 24.884

2.  Aβ43 aggregates exhibit enhanced prion-like seeding activity in mice.

Authors:  Alejandro Ruiz-Riquelme; Alison Mao; Marim M Barghash; Heather H C Lau; Erica Stuart; Gabor G Kovacs; K Peter R Nilsson; Paul E Fraser; Gerold Schmitt-Ulms; Joel C Watts
Journal:  Acta Neuropathol Commun       Date:  2021-05-10       Impact factor: 7.801

3.  Mutation screening of patients with Alzheimer disease identifies APP locus duplication in a Swedish patient.

Authors:  Håkan Thonberg; Marie Fallström; Jenny Björkström; Jacqueline Schoumans; Inger Nennesmo; Caroline Graff
Journal:  BMC Res Notes       Date:  2011-11-01

4.  Aβ43 is neurotoxic and primes aggregation of Aβ40 in vivo.

Authors:  Sylvie Burnouf; Marianna Karina Gorsky; Jacqueline Dols; Sebastian Grönke; Linda Partridge
Journal:  Acta Neuropathol       Date:  2015-04-11       Impact factor: 17.088

5.  Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer's Disease.

Authors:  Ina S Almdahl; Camilla Lauridsen; Per Selnes; Lisa F Kalheim; Christopher Coello; Beata Gajdzik; Ina Møller; Marianne Wettergreen; Ramune Grambaite; Atle Bjørnerud; Geir Bråthen; Sigrid B Sando; Linda R White; Tormod Fladby
Journal:  Front Aging Neurosci       Date:  2017-02-07       Impact factor: 5.750

6.  Effect of canola oil consumption on memory, synapse and neuropathology in the triple transgenic mouse model of Alzheimer's disease.

Authors:  Elisabetta Lauretti; Domenico Praticò
Journal:  Sci Rep       Date:  2017-12-07       Impact factor: 4.379

7.  Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer's Disease, But Has Similar Diagnostic Accuracy to Aβ42.

Authors:  Camilla Lauridsen; Sigrid B Sando; Ina Møller; Guro Berge; Precious K Pomary; Gøril R Grøntvedt; Øyvind Salvesen; Geir Bråthen; Linda R White
Journal:  Front Aging Neurosci       Date:  2017-06-28       Impact factor: 5.750

8.  (-)-Oleocanthal Nutraceuticals for Alzheimer's Disease Amyloid Pathology: Novel Oral Formulations, Therapeutic, and Molecular Insights in 5xFAD Transgenic Mice Model.

Authors:  Afsana Tajmim; Areli K Cuevas-Ocampo; Abu Bakar Siddique; Mohammed H Qusa; Judy Ann King; Khaldoun S Abdelwahed; Jafrin Jobayer Sonju; Khalid A El Sayed
Journal:  Nutrients       Date:  2021-05-18       Impact factor: 5.717

9.  The pathogenic aβ43 is enriched in familial and sporadic Alzheimer disease.

Authors:  Anna Sandebring; Hedvig Welander; Bengt Winblad; Caroline Graff; Lars O Tjernberg
Journal:  PLoS One       Date:  2013-02-11       Impact factor: 3.240

10.  Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.

Authors:  Elena Rodriguez-Vieitez; Laure Saint-Aubert; Stephen F Carter; Ove Almkvist; Karim Farid; Michael Schöll; Konstantinos Chiotis; Steinunn Thordardottir; Caroline Graff; Anders Wall; Bengt Långström; Agneta Nordberg
Journal:  Brain       Date:  2016-01-26       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.